Clinical trial
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
NCT00227318 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00227318 |
|---|---|
| Title | TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial |
| Official title | A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension Using Candesartan Cilexetil 16 mg in Patients With High Normal Blood Pressure (TROPHY) |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | ATACAND |
| Enrollment | 1,000 |
| Start date | Jul 1, 1998 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Sep 28, 2005 |
| Last update posted | Aug 30, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: